Renee Martin Email and Phone Number

• Over 27 years’ drug discovery and development experience in biopharmaceutical and multinational pharmaceutical companies: CuraSen Therapeutics, Anthera Pharmaceuticals, Roche Pharmaceuticals, Wellcome, GlaxoWellcome.• Medical Sciences expert, entrenched in design, development, deployment and analysis of clinical trials for determination of drug efficacy, safety, pharmacodynamics, and pharmacokinetics (Phase 0, 1, 2, 3) to comply with regulatory guidance for eventual application for marketing approval.• Data wrangler for nonclinical and clinical data, assimilating it into research strategy, corporate messaging, scientific publications, and global regulatory submissions to FDA, EMA, PMDA, Ministries of Health.• Matrix program leadership of drug discovery programs, from lead series identification, through lead optimization and clinical candidate selection. • Proven expertise in disease biology and molecular pharmacology as evidenced by publications on assessment of drug effect in CNS, inflammation and other disease areas, targeting inflammatory mediators, GPCRs, ion channels, enzymes and transporters.• Seasoned scientific spokesperson for candidate drug molecules, from the perspectives of both partnering (thorough, instant-access familiarity with candidate drug’s data and properties), and in-licensing (assessment of nonclinical and clinical efficacy and safety data, druggability, goodness-of-fit for portfolio).• Scientific agility evidenced by identification of opportunities for lifecycle expansion for portfolio assets into new, mechanistically-logical indications across inflammation, neuroscience and oncology disease areas, and subsequent optimization of nonclinical evaluations and clinical trials in collaboration with external experts.